You searched for "tarsal"
Retinoblastoma risk factors for recurrence
This study evaluates risk factors for local tumour recurrence of main solid tumour, subretinal seed, vitreous seed and new tumour formation in eyes with retinoblastoma (RB) management with primary chemotherapy over 20 years of follow-up. The study included 960 eyes...Germline mutation risk in solitary unilateral retinoblastoma
This study aimed to determine the true risk for germline mutation in a child presenting with solitary unilateral RB and whether this risk differs by age at presentation. This was a retrospective review of 482 cases from 1972-2020. Age groups...Importance of visual fields for detection of progression in glaucoma
1 October 2017
| Eulee Seow
|
EYE - Glaucoma
Early detection of progression of glaucoma, and escalating treatment is vital to maintain vision in patients. In this paper from the Early Manifest Glaucoma Trial (EMGT) group they compared the earliest detection of progression in visual fields and monoscopic optic...
A randomised, controlled trial of oral propranolol in infantile haemangioma
Since its use was first reported in the New England Journal in 2008, propranolol has become the preferred treatment for infantile haemangiomas. However, there is no consensus as to the optimum dose or duration of treatment and there is a...Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...Do topical steroids improve visual outcome in the treatment of bacterial keratitis?
The use of topical corticosteroids as an adjunctive treatment to antibiotics in the management of bacterial keratitis remains a controversial issue. The results of the Steroids for Corneal Ulcers Trial (SCUT) – a randomised, double-masked, placebo-controlled trial that recruited patients...An educational intervention to improve adherence to high-dosage patching regimen for amblyopia
This is a randomised trial of patients recruited between the periods of March 2006 and March 2008 from ophthalmology clinics in the Leicestershire area. A total of 62 children with newly diagnosed amblyopia were allocated randomly into two treatment arms...Pilot trial of Fluoxetine for post-stroke homonymous hemianopia
3 April 2024
| Lauren R Hepworth
|
EYE - Neuro-ophthalmology
The authors present a pilot randomised placebo controlled double blind trial assessing 20mg fluoxetine once daily for 90 days versus placebo in stroke survivors with isolated homonymous hemianopia. Exclusion criteria were extensive in terms of pre-existing ophthalmic or neurologic disease,...
App usage to improve compliance with amblyopia therapy
In this study, the authors report the development of the software ‘Magical patching’ for iOS and Android (for smartphones and tablets) as the first version of the amblyopia treatment Chulalongkoru university (ATCU) app. In this randomised controlled trial, they aimed...Progression in the Early Manifest Glaucoma Trial
1 August 2016
| Brian Ang
|
EYE - Glaucoma
The Early Manifest Glaucoma Trial (EMGT) had previously demonstrated without doubt that intraocular pressure reduction decreased the risk of progression in patients with early glaucoma. In this analysis of 306 eyes over eight years from the EMGT, perimetric and optic...
Comparison of treatment for hemianopia following stroke
1 August 2016
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Fresnel prisms, homonymous hemianopia, randomised controlled trial, recruitment, screening, stroke, visual search
The authors report the screening process and recruitment figures for a randomised controlled trial comparing interventions for post stroke homonymous hemianopia. Interventions included Fresnel prisms, visual search training and standard care (information only). Primary outcome measure was the change in...
Aflibercept, bevacizumab or ranibizumab for DMO
1 August 2016
| Brian Ang
|
EYE - Vitreo-Retinal
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...